- Home
- CRBP vs GALT Comparison
CRBP vs GALT Comparison
Compare CRBP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- GALT
- Stock Information
- Founded
- CRBP 2009
- GALT 2000
- Country
- CRBP United States
- GALT United States
- Employees
- CRBP N/A
- GALT N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- CRBP Health Care
- GALT Health Care
- Exchange
- CRBP Nasdaq
- GALT Nasdaq
- Market Cap
- CRBP 73.4M
- GALT 83.5M
- IPO Year
- CRBP N/A
- GALT N/A
- Fundamental
- Price
- CRBP $8.33
- GALT $2.60
- Analyst Decision
- CRBP Strong Buy
- GALT Buy
- Analyst Count
- CRBP 10
- GALT 2
- Target Price
- CRBP $53.56
- GALT $6.00
- AVG Volume (30 Days)
- CRBP 123.5K
- GALT 1.2M
- Earning Date
- CRBP 08-05-2025
- GALT 08-12-2025
- Dividend Yield
- CRBP N/A
- GALT N/A
- EPS Growth
- CRBP N/A
- GALT N/A
- EPS
- CRBP N/A
- GALT N/A
- Revenue
- CRBP N/A
- GALT N/A
- Revenue This Year
- CRBP N/A
- GALT N/A
- Revenue Next Year
- CRBP $150.03
- GALT N/A
- P/E Ratio
- CRBP N/A
- GALT N/A
- Revenue Growth
- CRBP N/A
- GALT N/A
- 52 Week Low
- CRBP $4.64
- GALT $0.73
- 52 Week High
- CRBP $61.90
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- CRBP 54.09
- GALT 70.66
- Support Level
- CRBP $8.10
- GALT $1.28
- Resistance Level
- CRBP $9.45
- GALT $1.36
- Average True Range (ATR)
- CRBP 0.52
- GALT 0.33
- MACD
- CRBP -0.08
- GALT 0.18
- Stochastic Oscillator
- CRBP 55.74
- GALT 52.40
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.